Literature DB >> 20184781

Genomic aberrations in borderline ovarian tumors.

Francesca Micci1, Lisbeth Haugom, Terje Ahlquist, Hege K Andersen, Vera M Abeler, Ben Davidson, Claes G Trope, Ragnhild A Lothe, Sverre Heim.   

Abstract

BACKGROUND: According to the scientific literature, less than 30 borderline ovarian tumors have been karyotyped and less than 100 analyzed for genomic imbalances by CGH.
METHODS: We report a series of borderline ovarian tumors (n = 23) analyzed by G-banding and karyotyping as well as high resolution CGH; in addition, the tumors were analyzed for microsatellite stability status and by FISH for possible 6q deletion.
RESULTS: All informative tumors were microsatellite stable and none had a deletion in 6q27. All cases with an abnormal karyotype had simple chromosomal aberrations with +7 and +12 as the most common. In three tumors with single structural rearrangements, a common breakpoint in 3q13 was detected. The major copy number changes detected in the borderline tumors were gains from chromosome arms 2q, 6q, 8q, 9p, and 13q and losses from 1p, 12q, 14q, 15q, 16p, 17p, 17q, 19p, 19q, and 22q. The series included five pairs of bilateral tumors and, in two of these pairs, informative data were obtained as to their clonal relationship. In both pairs, similarities were found between the tumors from the right and left side, strongly indicating that bilaterality had occurred via a metastatic process. The bilateral tumors as a group showed more aberrations than did the unilateral ones, consistent with the view that bilaterality is a sign of more advanced disease.
CONCLUSION: Because some of the imbalances found in borderline ovarian tumors seem to be similar to imbalances already known from the more extensively studied overt ovarian carcinomas, we speculate that the subset of borderline tumors with detectable imbalances or karyotypic aberrations may contain a smaller subset of tumors with a tendency to develop a more malignant phenotype. The group of borderline tumors with no imbalances would, in this line of thinking, have less or no propensity for clonal evolution and development to full-blown carcinomas.

Entities:  

Mesh:

Year:  2010        PMID: 20184781      PMCID: PMC2838832          DOI: 10.1186/1479-5876-8-21

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  43 in total

1.  Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals.

Authors:  M Kirchhoff; T Gerdes; H Rose; J Maahr; A M Ottesen; C Lundsteen
Journal:  Cytometry       Date:  1998-03-01

2.  Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.

Authors:  Lovisa Osterberg; Margaretha Akeson; Kristina Levan; Karolina Partheen; Britt-Marie Zetterqvist; Mats Brännström; György Horvath
Journal:  Cancer Genet Cytogenet       Date:  2006-06

3.  Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization.

Authors:  N G Wolf; F W Abdul-Karim; C Farver; E Schröck; S du Manoir; S Schwartz
Journal:  Genes Chromosomes Cancer       Date:  1999-08       Impact factor: 5.006

4.  Karyotypic analysis of 32 malignant epithelial ovarian tumors.

Authors:  R B Deger; S A Faruqi; J S Noumoff
Journal:  Cancer Genet Cytogenet       Date:  1997-07-15

5.  Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors.

Authors:  Khalil Helou; Hesed Padilla-Nash; Danny Wangsa; Elin Karlsson; Lovisa Osterberg; Per Karlsson; Thomas Ried; Turid Knutsen
Journal:  Cancer Genet Cytogenet       Date:  2006-10-01

6.  An abundance of p53 null mutations in ovarian carcinoma.

Authors:  J S Skilling; A Sood; T Niemann; D J Lager; R E Buller
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

7.  TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.

Authors:  H Skomedal; G B Kristensen; V M Abeler; A L Børresen-Dale; C Tropé; R Holm
Journal:  J Pathol       Date:  1997-02       Impact factor: 7.996

8.  Genomic aberrations in carcinomas of the uterine corpus.

Authors:  Francesca Micci; Manuel R Teixeira; Lisbeth Haugom; Gunnar Kristensen; Vera M Abeler; Sverre Heim
Journal:  Genes Chromosomes Cancer       Date:  2004-07       Impact factor: 5.006

9.  High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium.

Authors:  R S Cornelis; S L Neuhausen; O Johansson; A Arason; D Kelsell; B A Ponder; P Tonin; U Hamann; A Lindblom; P Lalle
Journal:  Genes Chromosomes Cancer       Date:  1995-07       Impact factor: 5.006

10.  Identification of two candidate tumor suppressor genes on chromosome 17p13.3.

Authors:  D C Schultz; L Vanderveer; D B Berman; T C Hamilton; A J Wong; A K Godwin
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

View more
  7 in total

Review 1.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

2.  A novel truncated form of HMGA2 in tumors of the ovaries.

Authors:  Antonio Agostini; Ioannis Panagopoulos; Ben Davidson; Claes Goran Trope; Sverre Heim; Francesca Micci
Journal:  Oncol Lett       Date:  2016-06-29       Impact factor: 2.967

3.  Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Authors:  Katherine Stemke-Hale; Kristy Shipman; Isidora Kitsou-Mylona; David G de Castro; Vicky Hird; Robert Brown; James Flanagan; Hani Gabra; Gordon B Mills; Roshan Agarwal; Mona El-Bahrawy
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

4.  High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour.

Authors:  Sithara Aravind; Sangeetha K Nayanar; R Varadharajaperumal; T V Satheeshbabu; Satheesan Balasubramanian
Journal:  J Clin Diagn Res       Date:  2017-06-01

5.  Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.

Authors:  Tobias Bürger; Hans-Ulrich Schildhaus; Reinhard Inniger; Joachim Hansen; Peter Mayer; Stefan Schweyer; Heinz Joachim Radzun; Philipp Ströbel; Felix Bremmer
Journal:  Diagn Pathol       Date:  2015-07-22       Impact factor: 2.644

6.  Loss of 11p11 is a frequent and early event in sporadic nonfunctioning pancreatic neuroendocrine neoplasms.

Authors:  Sven-Petter Haugvik; Ludmila Gorunova; Lisbeth Haugom; Anne Mette Eibak; Ivar Prydz Gladhaug; Sverre Heim; Francesca Micci
Journal:  Oncol Rep       Date:  2014-07-11       Impact factor: 3.906

7.  Genomic profile of ovarian carcinomas.

Authors:  Francesca Micci; Lisbeth Haugom; Vera M Abeler; Ben Davidson; Claes G Tropé; Sverre Heim
Journal:  BMC Cancer       Date:  2014-05-05       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.